Enhanced nuclear delivery and cytotoxic activity of hydro-xycamptothecin using o/w emulsions

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 10, Issue 1, 2007, Pages 61-70

  Zhao, Yongxing ^a,b   Gao, Jianqing ^a   Sun, Xiaoyi ^a   Chen, Hailiang ^a   Wu, Limao ^a   Liang, Wenquan ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHENGZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN DERIVATIVE; HYDROXYCAMPOTHECIN; LACTONE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL NUCLEUS; CELL STRUCTURE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CULTURE MEDIUM; CYTOPLASM; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG FORMULATION; DRUG MECHANISM; DRUG STABILITY; DRUG STRUCTURE; DRUG TARGETING; EMULSION; HELA CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TEMPERATURE; PH; PLASMA;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CELL NUCLEUS; EMULSIONS; FEMALE; HELA CELLS; HUMANS;

EID: 34247887699     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Rothenberg M.L. Topoisomerase I inhibitors: review and update. Ann Oncol, 8: 837-855, 1997.
2. Hsiang Y.H., Hertzberg R., Hecht S., Liu L.F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem, 260: 14873-14878, 1985.
3. Han J.Y., Lee D.H., Lee S.Y., Park C.G., Kim H.Y., Lee H.G., Lee J.J., Kim H.T., Lee J.S. Phase II study of weekly irinotecan plus capecitabine for chemotherapy-naive patients with advanced nonsmall cell lung carcinoma. Cancer, 104: 2759-2765, 2005.
4. Markman M. Topotecan as second-line therapy for ovarian cancer: dosage versus toxicity. Oncologist, 10: 695-697, 2005.
5. Yonemori K., Katsumata N., Yamamoto N., Kasamatsu T., Yamada T., Tsunematsu R., Fujiwara Y. A phase I study and pharmacologic evaluation of irinotecan and carboplatin for patients with advanced ovarian carcinoma who previously received platinum-containing chemotherapy. Cancer, 104: 1204-1212, 2005.
6. Hertzberg R.P., Caranfa M.J., Holden K.G., Jakas D.R., Gallagher G., Mattern M.R., Mong S.M., Bartus J.O., Johnson R.K., Kingsbury W.D. Modification of the hydroxy lactone ring of camptothecinFinhibition of mammalian topoisomerase-I and biological activity. J Med Chem, 32: 715-720, 1989.
7. Mi, Z., Burke, T.G.Differential interactions of camptothecin lactone and carboxylate forms with human blood components. Biochemistry, 33: 10325-10336, 1994.
8. Wani M.C., Ronman P.E., Lindley J.T., Wall M.E. Plant antitumor agents. 18. Synthesis and biological activity of camptothecin analogues. J Med Chem, 3: 554-560, 1980.
9. Burke T.G., Mi Z.H. Preferential binding of the carboxylate form of camptothecin by human serum albumin. Anal Biochem, 212: 285-287, 1993.
10. Croce A.C., Bottiroli G., Supino R., Favini E., Zuco V., Zunino F. Subcellular localization of the camptothecin analogues, topotecan and gimatecan. Biochem Pharmacol, 67: 1035-1045, 2004.
11. Sætern A.M., Brandl M., Bakkelund W.H., Sveinbjørnsson B. Cytotoxic effect of different camptothecin formulations on human colon carcinoma in vitro. Anti-Cancer Drugs, 15: 899-906, 2004.
12. Paranjpe P.V., Stein S., Sinko P.J. Tumor-targeted and activated bioconjugates for improved camptothecin delivery. Anti-Cancer Drugs, 16: 763-775, 2005.
13. Minko T., Paranjpe P.V., Qiu B., Lalloo A., Won R., Sinko P.J. Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethyleneglycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells. Cancer Chemother Pharmacol, 50: 143-150, 2002.
14. Williams J., Lansdown R., Sweitzer R., Romanowski M., LaBell R., Ramaswami R., Unger E. Nanoparticle drug delivery system for intravenous delivery of topoisomerase inhibitors. J Control Release, 9: 167-172, 2003.
15. Mallery S.R., Shenderova A., Pei P., Begum S., Ciminieri J.R., Wilson R.F., Casto B.C., Schuller D.E., Morse M.A. Effects of 10-hydroxycamptothecin, delivered from locally injectable poly(lactide-co-glycolide) microspheres, in a murine human oral squamous cell carcinoma regression model. Anticancer Res, 21: 1713-1722, 2001.
16. Zhao Y.X., Gao J.Q., Qiao H.L., Chen H.L., Liang W.Q. Development and validation of a sensitive reversed-phase HPLC method to determine intracellular accumulation of hydroxycamptothecin. J Pharm Biomed Anal, 41: 1007-1010, 2006.
17. Lundberg B.B., Risovic V., Ramaswamy M., Wasan K.M. A lipophilic paclitaxel derivative incorporated in a lipid emulsion for parenteral administration. J Control Release, 86: 93-100, 2003.
18. Zhang X.G., Kirsch L.E. An assessment of techniques for evaluating the physical stability of parenteral emulsions. PDA. J Pharm Sci Technol, 57: 300-315, 2003.
19. Wang Y., Eksborg S., Lewensohn R., Lindberg A., Liliemark E. In vitro cellular accumulation and cytotoxicity of liposomal and conventional formulations of daunorubicin and doxorubicin in resistant K562 cells. Anticancer Drugs, 10:921-928, 1999.
20. Serpe L., Guido M., Canaparo R., Muntoni E., Cavalli R., Panzanelli P., Della Pepal C., Bargoni A., Mauro A., Gasco MR., Eandi M., Zara GP.Intracellular accumulation and cytotoxicity of doxorubicin with different pharmaceutical formulations in human cancer cell lines. J Nanosci Nanotechnol, 6(9-10):3062-3069, 2006.
21. Xiong X.B., Huang Y., Lu W.L., Zhang H., Zhang X., Zhang Q. Enhanced intracellular uptake of sterically stabilized liposomal Doxorubicin in vitro resulting in improved antitumor activity in vivo. Pharm Res, 22(6):933-939, 2005.
22. Shabbits J.A., Mayer L.D. Intracellular delivery of ceramide lipids via liposomes enhances apoptosis in vitro. Biochim Biophys Acta, 1612: 98-106, 2003.
23. van, Ark-Otte J., Kedde M.A., van, der, Vijgh W.J., Dingemans A.M., Jansen W.J., Pinedo H.M., Boven E., Giaccone G. Determinants of CPT-11 and SN-38 activities in human lung cancer cells. Br J Cancer, 77: 2171-2176, 1998.
24. Gabr A., Kuin A., Aalders M., El-Gawly H., Smets L.A. Cellular pharmacokinetics and cytotoxicity of camptothecin and topotecan at normal and acidic pH. Cancer Res, 57: 4811-4816, 1997.
25. Pratesi G., Beretta G.L., Zunino F. Gimatecan, a novel camptothecin with a promising preclinical profile. Anticancer Drugs, 15: 545-552, 2004.
26. Merdan T., Kopecek J., Kissel T. Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. Adv Drug Deliv Rev, 54: 715-758, 2002.
27. Wheeler J.J., Wong K.F., Ansell S.M., Masin D., Bally M.B. Polyethylene glycol modified phospholipids stabilize emulsions prepared from triacylglycerol. J Pharm Sci, 83: 1558-1564, 1994.
28. Lahiri D.K., Ge Y. Electrophoretic mobility shift assay for the detection of specific DNA-protein complex in nuclear extracts from the cultured cells and frozen autopsy human brain tissue. Brain Res Brain Res Protoc, 5: 257-265, 2000.
29. Spector D.; Goldman R.; Leinwand L., Cells: A Laboratory Manual Volume 1: Culture and Biochemical Analysis of cells. Cold Spring Harbor Laboratory Press, USA, 1997.
30. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assay. J Immunol Methods, 65: 55-63, 1983.
31. Shenderova, A., Burke, T.G., Schwendeman, S.P. The acidic microclimate in poly(lactide-co-glycolide) microspheres stabilizes camptothecins. Pharm Res, 16: 241-248, 1999
32. Nielsen D.L. Mechanisms and functional aspects of multidrug resistance in Ehrlichascites tumour cells. Dan Med Bull, 51: 393-414, 2004.
33. Kim T.W., Chung H., Kwon I.C., Sung H.C., Jeong S.Y. Optimization of lipid composition in cationic emulsion as in vitro and in vivo transfection agents. Pharm Res, 18: 54-60, 2001.
34. Min K.A., Lee S.K., Kim C.K. Improved gene expression pattern using Epstein-Barr virus (EBV)-based plasmid and cationic emulsion. Biomaterials, 26: 1063-1070, 2005.
35. Kim T.W., Chung H., Kwon I.C., Sung H.C., Jeong S.Y. Polycations enhance emulsion-mediated in vitro and in vivo transfection. Int J Pharm, 295: 35-45, 2005.